By retrospective analysis of 13 000 blood samples obtained from 248 patients receiving FK 506 therapy, we compared the suitability of plasma with that of whole blood as the matrix for therapeutic drug monitoring of FK 506. The plasma concentrations did not correlate with the concentrations in whole blood (r = 0.56). In contrast to plasma samples (analyzed by enzyme immunoassay), FK 506 was detectable in all whole-blood samples (analyzed by enzyme immunoassay/microparticle enzyme immunoassay). The inter-and intraindividual variations of FK 506 measurements were greater in plasma than in whole blood. Moreover, plasma concentrations correlated only poorly with clinical events. There was a tendency to greater plasma concentrations being measured during episodes of toxicity, but no clear difference was evident between stable course and rejection. In whole-blood specimens, a correlation between reduced or increased FK 506 concentrations and rejection or toxicity, respectively, was observed. The discriminatory power of wholeblood values was greater for the differentiation between toxicity and stable course than between rejection and stable course. We therefore recommend whole blood rather than plasma as the matrix for therapeutic monitoring of FK 506 concentrations.
Patientsand Clinical Course
Patients. In this study we retrospectively analyzed FK 506 concentrations in blood or plasma as detected by ETA or MEIA (performed with an IMx from Abbott Labs., Abbott Park, IL) in 13 000 different blood samples obtained from 248 patients receiving FK 506 mmmunosuppression treatment. Of these patients, 182 had received transplants in this institution (126 patients had received a liver graft, 45 a kidney, 5 a lung, and 6 multiple organ grafts). The other 66 patients had received a liver (n = 50), a kidney (n = 14), or a combined kidney/pancreas transplant (n = 2) in other transplant centers in Germany; blood or plasma specimen obtained from these patients had been shipped to our laboratory. The frequency of FK 506 determinations was daily during the first week of treatment, three times a week during the subsequent hospital course, and weekly to monthly during the outpatient course.
All patients included into the study participated in several clinical trials investigating the usefulness of FK 506 for primary or rescue immunosuppression after transplantation; all had signed appropriate informed consent forms. All studies were performed according to the Helsinki Declaration of 1983 and had passed our institutional review board.
Definition of clinical episodes of rejection or toxicity. Episodes of clinical events were defined as follows: Rejection was defined as biopsy-proven graft rejection with decrease in transplant function (e.g., increase in creatmine or the transaminases), necessitating treatment.
Acute nephrotoxicity
was defined as an increase in creatinine to >140 molfL in adults or to >50% above baseline in children. The FK 506 dose had to be reduced and other possible causes of kidney dysfunction ruled out. (13) . Quality controls, e.g., internal control samples provided by the manufacturer as well as external samples sent from the European Reference Laboratory for the MEIA roundrobin test, were analyzed at regular intervals.
The limit of detection of the MEIA was 5 fLg/L. Whole-blood samples yielding a result <5 gfL in the MEIA were remeasured with the wb-sl-EIA. For better comparability, the wb-sl-EIA and MEJA were cross-calibrated with each other.
Results

FK 506 concentrations
were detected in 80 pairs of blood and plasma samples obtained from 25 different liver-graft recipients. Analyzing these samples by p1-ETA, wb-ll-EIA, wb-sl-EIA and MEJA showed that the plasma concentrations did not correlate with the wholeblood values (r = 0.56, see Fig. 1 ). Whole-blood concentrations measured on the same set of blood samples by both ETA and MEIA were significantly correlated: r = 0.919; P = 0.006 (paired t test; see Fig. 2 ). For this analysis, we evaluated FK 506 detected in 11 000 different plasma or whole-blood samples. In a second subgroup of 1000 samples the plasma and whole-blood concentrations had been analyzed in parallel. As shown in Table  1 Plasma and whole-blood concentrations were retrospectively correlated with clinical events such as rejection or toxicity in the liver-graft recipients.
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The results (Fig. 3) showed that the plasma concentrations measured during different clinical episodes ranged between 0.05 and 50.0 .tgfL, whereas the overall variation in whole-blood content ranged from 2.0 to 80.0 pg/L. Plasma concentrations of FK 506 only poorly correlated with clinical events. There was a tendency to increased plasma values during episodes of toxicity, but no clear difference could be found between the concentrations detected during stable clinical course and those measured during graft rejection. Plotting plasma FK 506 vs bilfrubin did not significantly increase the clinical correlation (Fig. 3, top) .
Whole-blood specimens showed a correlation between decreased or increased FK 506 concentrations and rejection or toxicity, respectively.
Depending on the patients' liver function (Fig. 3, bottom) In this patient a massive accumulation of FK 506 in whole blood (wb-U-EIA) but not in plasma was observed. These high concentrations in whole blood correlated with clinical symptoms of FK 506 toxicity (e.g., neuro-and nephrotoxicity).
After interruption of FK 506 therapy, kidney function stabilized and neurologic symptoms improved. The predictive value of increased FK 506 in plasma or whole blood for clinical manifestations of FK 506 toxicity in liver-graft recipients ranged between 41% and 80% ( Table 2 ). There was a tendency to somewhat higher values if whole blood was used as matrix, but this difference was not significant.
In general, the predictive value of high FK 506 in plasma or whole blood was greater in the first postoperative month than later. On May 1, 1993, the matrix for FK 506 TDM in our laboratory was changed from plasma to whole blood. but switching the analytical matrix gave a mean wholeblood concentration of 140 jgfL. After dose reductions, the whole blood values gradually decreased to a mean of 9.0 gfL. In the initial assays of whole blood, 23.5% of the patients presented with concentrations >20.0 p.g/L; 75% of these patients showed clinically manifest FK 506 toxicity.
In two cohorts of consecutive patients after primary liver (n = 36) or kidney (n = 32) transplantation, we prospectively used the whole-blood concentrations to adjust the FK 506 dose. The clinical course in these two groups of patients is shown in Fig. 6 . Despite the use of entirely different FK 506 doses in the two groups the FK 506 blood concentrations detectable in the first month after transplantation were comparable.
In the long
term, FK 506 concentrations (as well as doses) were higher in the kidney transplant patients, but there was no difference in the frequency of episodes of FK 506 toxicity (e.g., nephrotoxicity) between both groups. During the first 6 months after transplantation, acute graft rejection requiring treatment was observed in 25% of Using plasma as matrix for TDM has several disadvantages over using whole blood. The distribution of FK 506 between plasma and blood cells depends on the hematocrit and the temperature of the sample (16-20) . For example, the low sensitivity of the EIA that currently is the only assay suitable for detecting FK 506 in plasma can be partially overcome by using 36#{176}C plasma separation, which leads to 20-50% higher results for FK 506 determination (15) . However, some of our patients with plasma concentrations below the limit of detection presented with whole-blood concentrations >20 pg/L and clinically manifest toxicity. Therefore, it is unlikely that the 36#{176}C plasma EJA might be able to differentiate these patients from patients without toxicity. Moreover, the interindividual variation (1000-fold) in FK 506 plasma concentrations is much higher than that in whole blood (40-fold), which makes difficult the definition of potential therapeutic windows. Finally, while the predictive value of increased plasma concentrations for FK 506 toxicity is comparable with that of whole blood, no lower limit for plasma values can be defined for avoidance of graft rejection. Thus, plasma concentrations cannot differentiate between stable course and underimmunosuppression (Fig. 3) . In contrast, if liver function is taken into account (Fig. 3, bottom) , the use of whole-blood FK 506 concentrations allows the definition of lower and upper target values in a way that therapeutic windows can be established.
Based on these arguments, the matrix for FK 506 TDM should be whole blood.
In a recently published study ascertaining the preferred matrix for FK 506 TDM, B#{226}ckman et al. (15) found plasma (36#{176}C) to be somewhat superior to whole blood. In their study of blood or plasma samples obtained from a smaller group of liver-graft patients, both whole-blood and plasma concentrations were measured during episodes of FK 506 toxicity. After a year of treatment, however, only the yearly mean plasma concentrations correlated with an observed loss in glomerular filtration rate. Most of those patients were treated with relatively high doses of FK 506 (initial dose, 0.30 mg/kg daily in primary liver-graft recipients), which is also reflected by the high mean whole-blood concentration measured in stable liver-graft recipients in that study (15.2 ± 2.1 pg/L), well above the upper target for stable patients in our group. Plasma samples obtained from patients on such a high dose of FK 506 might yield detectable FK 506 in a higher percentage of patients than was observed in our study, thus eliminating one of the major pitfalls of plasma for TDM. However, patients on low-dose FK 506 stifi have a high percentage of plasma samples containing FK 506 below the limit of detection of the standard ETA. Compared with the whole-blood ETA, the MEIA is less laborious and also less susceptible to technical failures. In addition, its precision is greater than that of the ETA (11, 13, 17) . Therefore, we consider the MEJA the method of choice for clinical drug monitoring in whole blood. However, the detection limit of the whole-blood IMx, 5.0 p.gfL, is too low for routine clinical use (11, 13), and samples containing <5.0 gfL FK 506 should therefore be reassayed with a whole-blood ETA.
The ratio between FK 506 whole-blood concentration and FK 506 dose was higher in liver-transplant patients than in kidney-transplant patients. (Fig. 3,  bottom) . In patients treated with CsA for immunosuppression, liver dysfunction (and subsequent accumulation of CsA metabolites) can lead to a 5-to 10-fold increase in the CsA concentrations measured by nonspecific CsA assays (23) .
In the long term, liver-graft patients were treated with lower FK 506 doses and blood concentrations than the kidney-graft patients (Fig. 6) . Nonetheless, no apparent difference in the frequency of graft rejection was observed between these two groups of patients. Most probably, because of microchimerism, which is more pronounced after liver than after kidney transplantation (24), liver grafts require less immunosuppression and are more resistant to immunologic destruction (25) than are kidney or heart transplants.
Indeed, stable long-term liver-graft patients can be successfully weaned off immunosuppression without subsequent rejection (24), which is not possible in kidney or heart recipients. Thus, the observation of lower FK 506 dosing and target value requirements in liver-transplant patients might be the reflection of a lower total immunosuppressive load necessary for prevention of graft rejection in these patients.
In summary, our data clearly support whole blood as the preferable matrix for FK 506 TDM. The assay of choice currently seems to be the MEIA, although the detection limit of this assay should be improved. FK 506 concentrations measured by the MEIA are influenced by cross-reacting metabolites; their cross-reactivity, however, seem to be low. If liver function is taken into account, therapeutic windows for FK 506 TDM (Table 3 ) can be defined.
